CN103908542B - A kind of compound preparation treating rheumatoid arthritis and preparation method thereof - Google Patents
A kind of compound preparation treating rheumatoid arthritis and preparation method thereof Download PDFInfo
- Publication number
- CN103908542B CN103908542B CN201410180064.4A CN201410180064A CN103908542B CN 103908542 B CN103908542 B CN 103908542B CN 201410180064 A CN201410180064 A CN 201410180064A CN 103908542 B CN103908542 B CN 103908542B
- Authority
- CN
- China
- Prior art keywords
- parts
- fici pumilae
- caulis
- weight
- spirulina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 18
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 14
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 14
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 14
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 14
- 229940082787 spirulina Drugs 0.000 claims abstract description 14
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 229960001929 meloxicam Drugs 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 description 16
- 208000006820 Arthralgia Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229960001639 penicillamine Drugs 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- -1 isobutyl phenylpropyl Chemical group 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000009395 Zhengqing Fengtongning Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940111120 gold preparations Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The compound preparation of the treatment rheumatoid arthritis of the present invention；Crude drug by following parts by weight: Caulis fici pumilae (Fructus Fici Pumilae) 11～15 parts, Radix Sanguisorbae 5～8 parts, Cortex Phellodendri 5～7 parts, Rhizoma Belamcandae 5～7 parts, Caulis Polygoni Multiflori 4～6 parts, Rhizoma Homalomenae 6～9 parts, Semen Ziziphi Spinosae 8～12 parts, Herba Typhonii gigantei 1～3 parts, spirulina 11～15 parts, chondroitin sulfate 8～12 parts, meloxicam 9～13 parts are made.Preparation method, comprises the following steps: a, the Radix Sanguisorbae by described parts by weight, Cortex Phellodendri, Rhizoma Belamcandae, Caulis Polygoni Multiflori, Semen Ziziphi Spinosae are respectively adopted reflux extraction, extract extractum, dry powder process, mix homogeneously；B, the Caulis fici pumilae (Fructus Fici Pumilae) by described parts by weight, Rhizoma Homalomenae, Herba Typhonii gigantei, spirulina, chondroitin sulfate, meloxicam are respectively prepared 200～400 mesh powder, together with the mixture in step a, join in V-Mixer, mix homogeneously.C, by the medicated powder in step b, load in capsule according to 0.64 gram every.
Description
Technical field
The invention belongs to field of medicaments, a kind of compound preparation treating rheumatoid arthritis and preparation method thereof.
Background technology
Rheumatoid arthritis is a kind of chronic systemic autoimmune disease based on arthropathy.Main clinical manifestation is the arthralgia caused by Minor articulus synovial membrane, and cartilage destruction, joint space narrow then, and late period causes joint stiffness, deformity, dysfunction because of serious bone destruction, absorption.Prevalence in China's rheumatoid arthritis is 0.24-0.5%, and women is more than male, about 2-3:1, and any age all can fall ill, with 20-50 year most.Primary disease mostly is a kind of repeated relapsing disease, and disability rate is higher, prognosis mala, there is presently no good radical cure method.
Pharmacotherapy: (one) salicylate: aspirin is still for the choice drug for the treatment of rheumatoid arthritis.(2) indometacin: nonsteroid anti-inflammatory drugs, effect is preferable, its analgesia, brings down a fever and antiinflammatory action is the strongest.(3) this acid of isobutyl phenylpropyl alcohol: antiinflammatory, analgesia and antipyretic effect are all strong compared with aspirin more than 10 times, and side effect is little compared with aspirin.(4) 17-hydroxy-11-dehydrocorticosterone: have significant curative effect to acute inflammation, prolonged application side effect is more, easily recurs after drug withdrawal.(5) penicillamine: application penicillamine treatment, in addition to making joint symptoms and alleviating, can make erythrocyte sedimentation rate and c reactive protein reduce, and rheumatoid factor transfers feminine gender to.(6) CP.(7) Radix Tripterygii Wilfordii: there is the effect such as antiinflammatory, antibacterial, regulation immunity, blood circulation promoting and blood stasis dispelling, parasite killing.(8) gold preparation: may interfere with the biochemical reaction of cell.Arthralgia and deadlock in morning being had obvious curative effects, erythrocyte sedimentation rate and c reactive protein also can be made to take a turn for the better, effective percentage is up to 70-90%.(9) immunosuppressant: have certain curative effect, dust head to have cyclophosphamide, azathioprine to primary disease.(10) the efficient medicine of rheumatoid arthritis: kanlisha coarse sand granules.
Summary of the invention
It is an object of the invention to provide a kind of compound preparation treating rheumatoid arthritis and preparation method thereof.
The compound preparation of the treatment rheumatoid arthritis of the present invention；Crude drug by following parts by weight: Caulis fici pumilae (Fructus Fici Pumilae) 11～15 parts, Radix Sanguisorbae 5～8 parts, Cortex Phellodendri 5～7 parts, Rhizoma Belamcandae 5～7 parts, Caulis Polygoni Multiflori 4～6 parts, Rhizoma Homalomenae 6～9 parts, Semen Ziziphi Spinosae 8～12 parts, Herba Typhonii gigantei 1～3 parts, spirulina 11～15 parts, chondroitin sulfate 8～12 parts, meloxicam 9～13 parts are made.
As optimization, the compound preparation of this treatment rheumatoid arthritis, by the crude drug of following parts by weight: Caulis fici pumilae (Fructus Fici Pumilae) 12 parts, Radix Sanguisorbae 6 parts, Cortex Phellodendri 5 parts, Rhizoma Belamcandae 5 parts, Caulis Polygoni Multiflori 4 parts, Rhizoma Homalomenae 8 parts, Semen Ziziphi Spinosae 10 parts, Herba Typhonii gigantei 2 parts, spirulina 13 parts, chondroitin sulfate 10 parts, meloxicam 11 parts are made.
The method preparing the compound preparation of this treatment rheumatoid arthritis, comprises the following steps:
A, the Radix Sanguisorbae by described parts by weight, Cortex Phellodendri, Rhizoma Belamcandae, Caulis Polygoni Multiflori, Semen Ziziphi Spinosae are respectively adopted reflux extraction, extract extractum, dry powder process, mix homogeneously；
B, the Caulis fici pumilae (Fructus Fici Pumilae) by described parts by weight, Rhizoma Homalomenae, Herba Typhonii gigantei, spirulina, chondroitin sulfate, meloxicam are respectively prepared 200～400 mesh powder, together with the mixture in step a, join in V-Mixer, mix homogeneously；
C, by the medicated powder in step b, load in capsule according to 0.64 gram every.
The present invention treats in the compound preparation of rheumatoid arthritis, and Caulis fici pumilae (Fructus Fici Pumilae) dispels the wind, and dampness removing is invigorated blood circulation, removing toxic substances.Control phoenix pain of dampness syndrome, dysentery, gonorrhea, traumatic injury, carbuncle furuncle, antiinflammatory.
Radix Sanguisorbae cooling blood for hemostasis, heat-clearing and toxic substances removing, sore of subsiding a swelling.Main haematemesis, spitting of blood, epistaxis, hematuria, have blood in stool, hemorrhoidal bleeding, dysentery, metrorrhagia, leucorrhea with red and white discharge, sore, carbuncle and painful swelling, eczema, pudendal pruritus, burn due to hot liquid or fire, snake bite and insect sting.
Cortex Phellodendri heat clearing away.Dampness, pathogenic fire purging, removing toxic substances.Control hematodiarrhoea, have loose bowels, quench one's thirst, jaundice, flaccidity, nocturnal emission, stranguria with turbid discharge, hemorrhoid, have blood in stool, also under leucorrhea, hectic fever due to YIN-deficiency consumptive fever, conjunctival congestion and swelling pain, aphtha of the mouth and tongue, sore swollen toxin.
Rhizoma Belamcandae is used for experiencing wind heat, or expectorant heat stops up the diseases such as the laryngopharynx swelling and pain caused by containing.For diseases such as accumulation and obstruction of sputum, cough and asthmas.Laryngopharynx swelling and pain, sore throat is obstructed, constipation and anuresis, and all medicines are not imitated, abdominal part hydrops, skin turn black, acute mastitis from the beginning of.
Caulis Polygoni Multiflori is put down nontoxic, sweet and slightly bitter taste, enters the heart, Liver Channel, has effect of tranquilizing and blood nourishing, dispelling wind and removing obstruction in the collateral, cures mainly the diseases such as deficiency of YIN insufficiency of blood, restlessness of asrhenia type and insomnia, rheumatic arthralgia, itchy skin eruption.
Rhizoma Homalomenae has the effects such as wind-damp dispelling, relaxing muscles and tendons and activating QI and blood in the collateral, pain relieving, detumescence.Cure mainly rheumatic arthralgia, podomere acid is educated, muscles and bones flaccidity is soft, traumatic injury, stomachache, carbuncle skin ulcer are swollen.
The vexatious insomnia of Semen Ziziphi Spinosae master, umbilicus pain up and down, blood turns chronic diarrhea, sweating due to debility excessive thirst, invigorating middle warmer, the liver benefiting gas, hard muscles and bones, helps cloudy gas, makes us fertile strong.
Herba Typhonii gigantei tuber with for medicine, the expectorant that can dispel the wind, by cold-damp, spasmolytic, control headache, facial hemiparalysis, hemiplegia, tetanus, traumatic injury impairment caused by overstrain, numb limbs and tense tendons, aphasia due to apoplexy, lymphoid tuberculosis, snake bite and insect sting etc..
Containing the highest acid and gamma-linolenic in spirulina, have and promote calcium absorption, improve immunity, prevent metabolism disorder and prevent the function of aging.Acid and gamma-linolenic is the precursor of prostaglandin, becomes prostaglandin under the effect of oxygenase, and prostaglandin to reproduction, cardiovascular, is breathed, digested and nervous system all has effect.Polysaccharide in spirulina, has radiation-resistant function, and by enhancing human body immunity power.Additionally spirulina polysaccharide can improve the activity of the SOD in blood plasma, reduces the generation of lipid peroxide, has the effect of defying age.
Chondroitin sulfate is mainly used in treating hyperlipemia.Its clinical practice includes: 1. chondroitin sulfate as health food or health care medicine prolonged application in diseases such as preventing and treating coronary heart diseases and angina pectoris, myocardial infarction, coronary atherosclerosis, myocardial ischemia, without obvious toxic and side effects, the M & M of patients with coronary heart disease can be significantly reduced.2. chondroitin sulfate is used for treating neuralgia, nervous migraine, arthralgia, arthritis and omoplate arthralgia, abdominal postoperative pain etc..
Meloxicam, for 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1；NSAID (non-steroidal anti-inflammatory drug), it is adaptable to rheumatoid arthritis, the treatment of painful osteoarthritis.This compound preparation, expelling wind and removing dampness, between removing obstruction in the collateral to relieve pain, relaxing muscles and tendons and activating QI and blood in the collateral, each component, cooperative effect highlights；Treatment rheumatoid arthritis with remarkable effect.
Relevant clinical data is as follows:
Physical data: choose patient with rheumatoid arthritis 200 example, is randomly divided into treatment group 100 example and matched group 100 example, and the data such as two groups of sexes, age, the course of disease, state of an illness weights compares, and no significant difference, without concrete comparability.
Diagnostic criteria: all patients all meet the clinical criteria in American Rheumatism Association's diagnostic criteria of 1987 and " Chinese medical disease Standardization of diagnosis and curative effect " about arthromyodynia.Contraindication: 1. serious hepatic and kidney function obstacle or hematological abnormalities or activeness ulcer patient, tumor, mental sickness, fracture；2. hyperirritability body constitution person；3. once with medicine persons such as Yingpingwanbixiao sheet, methotrexate, penicillamine, chloroquine gold preparations in 1 month；4. anemia of pregnant woman, women breast-feeding their children.Patient articular's pain and swelling, have tenderness, and morning is stiff.X line.
Therapeutic Method: treatment group, compound preparation in the embodiment of the present invention 1,3 times on the 1st, 1 time 3, oral；Matched group, uses Zhengqing Fengtongning Retard Tablets 3 times on the 1st, 1 time 3, oral, take continuously 1 month 1 course for the treatment of, 3 courses for the treatment of of observing time.Before treatment, treat and respectively do the physico-chemical examinations such as rheumatoid factor, erythrocyte sedimentation rate, anti-O, c reactive protein, x line film making 1 time in 1 month, 2 months, 3 months.
Therapeutic evaluation: before and after treatment, two groups of patients are carried out following index evaluation: morning deadlock, the average grip of both hands, arthralgia (tenderness) number, arthroncus number, joint movement disorder index, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) quantitatively, rest pain, patient evaluate, doctor evaluation.Effective turning out cloudy for RF or be remarkably decreased, erythrocyte sedimentation rate is normal, and morning is stiff and arthralgia disappears, and joint motion is freely.Effectively declining 2/3 for RF, erythrocyte sedimentation rate is normal or < 30 mm/h arthroncuss, tenderness number reduce 50%.Being improved as RF and erythrocyte sedimentation rate all has decline, deadlock time in morning to shorten earlier above, arthralgia reduces.Invalid for symptom without improve.The results are shown in Table 1.
Detailed description of the invention
Example given below intends that the invention will be further described, but is not to be construed as limiting the scope of the invention, and those skilled in the art, according to some nonessential improvement and adjustment to the present invention of present invention, still fall within protection scope of the present invention.
Embodiment 1, a, take Radix Sanguisorbae 6 grams, Cortex Phellodendri 5 grams, Rhizoma Belamcandae 5 grams, Caulis Polygoni Multiflori 4 grams, Semen Ziziphi Spinosae 10 grams are respectively adopted reflux extraction, extract extractum, dry powder process, mix homogeneously；B, take Caulis fici pumilae (Fructus Fici Pumilae) 12 grams, Rhizoma Homalomenae 8 grams, Herba Typhonii gigantei 2 grams, spirulina 13 grams, chondroitin sulfate 10 grams, meloxicam 11 grams are respectively prepared 200～400 mesh powder, together with the mixture in step a, join in V-Mixer, mix homogeneously.C, by the medicated powder in step b, load in capsule according to 0.64 gram every.
Embodiment 2, a, take Radix Sanguisorbae 5 grams, Cortex Phellodendri 5 grams, Rhizoma Belamcandae 5 grams, Caulis Polygoni Multiflori 4 grams, Semen Ziziphi Spinosae 8 grams are respectively adopted reflux extraction, extract extractum, dry powder process, mix homogeneously；B, take Caulis fici pumilae (Fructus Fici Pumilae) 11 grams, Rhizoma Homalomenae 6 grams, Herba Typhonii gigantei 1 gram, spirulina 11 grams, chondroitin sulfate 8 grams, meloxicam 9 grams are respectively prepared 200～400 mesh powder, together with the mixture in step a, join in V-Mixer, mix homogeneously.C, by the medicated powder in step b, load in capsule according to 0.64 gram every.
Embodiment 3, a, take Radix Sanguisorbae 8 grams, Cortex Phellodendri 7 grams, Rhizoma Belamcandae 7 grams, Caulis Polygoni Multiflori 6 grams, Semen Ziziphi Spinosae 12 grams are respectively adopted reflux extraction, extract extractum, dry powder process, mix homogeneously；B, take Caulis fici pumilae (Fructus Fici Pumilae) 15 grams, Rhizoma Homalomenae 9 grams, Herba Typhonii gigantei 3 grams, spirulina 15 grams, chondroitin sulfate 12 grams, meloxicam 13 grams are respectively prepared 200～400 mesh powder, together with the mixture in step a, join in V-Mixer, mix homogeneously.C, by the medicated powder in step b, load in capsule according to 0.64 gram every.
Claims (2)
1. the compound preparation treating rheumatoid arthritis；It is characterized in that by the crude drug of following parts by weight: Caulis fici pumilae (Fructus Fici Pumilae) 11～15 parts, Radix Sanguisorbae 5～8 parts, Cortex Phellodendri 5～7 parts, Rhizoma Belamcandae 5～7 parts, Caulis Polygoni Multiflori 4～6 parts, Rhizoma Homalomenae 6～9 parts, Semen Ziziphi Spinosae 8～12 parts, Herba Typhonii gigantei 1～3 parts, spirulina 11～15 parts, chondroitin sulfate 8～12 parts, meloxicam 9～13 parts；Made by following steps:
A, the Radix Sanguisorbae by described parts by weight, Cortex Phellodendri, Rhizoma Belamcandae, Caulis Polygoni Multiflori, Semen Ziziphi Spinosae are respectively adopted reflux extraction, extract extractum, dry powder process, mix homogeneously；
B, the Caulis fici pumilae (Fructus Fici Pumilae) by described parts by weight, Rhizoma Homalomenae, Herba Typhonii gigantei, spirulina, chondroitin sulfate, meloxicam are respectively prepared 200～400 mesh powder, together with the mixture in step a, join in V-Mixer, mix homogeneously；
C, by the medicated powder in step b, load in capsule according to 0.64 gram every.
The compound preparation for the treatment of rheumatoid arthritis the most according to claim 1, it is characterised in that by the crude drug of following parts by weight: Caulis fici pumilae (Fructus Fici Pumilae) 12 parts, Radix Sanguisorbae 6 parts, Cortex Phellodendri 5 parts, Rhizoma Belamcandae 5 parts, Caulis Polygoni Multiflori 4 parts, Rhizoma Homalomenae 8 parts, Semen Ziziphi Spinosae 10 parts, Herba Typhonii gigantei 2 parts, spirulina 13 parts, chondroitin sulfate 10 parts, meloxicam 11 parts are made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180064.4A CN103908542B (en) | 2014-04-30 | 2014-04-30 | A kind of compound preparation treating rheumatoid arthritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180064.4A CN103908542B (en) | 2014-04-30 | 2014-04-30 | A kind of compound preparation treating rheumatoid arthritis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103908542A CN103908542A (en) | 2014-07-09 |
| CN103908542B true CN103908542B (en) | 2016-11-23 |
Family
ID=51034746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410180064.4A Expired - Fee Related CN103908542B (en) | 2014-04-30 | 2014-04-30 | A kind of compound preparation treating rheumatoid arthritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103908542B (en) |
-
2014
- 2014-04-30 CN CN201410180064.4A patent/CN103908542B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| Ⅱ型胶原注射骨关节炎时C-反应蛋白及类风湿因子的表达;雷静等;《中国组织工程研究》;20130312;第17卷(第11期);第2007-2012页 * |
| 甲氨蝶呤和硫酸软骨素联合雷公藤小剂量治疗类风湿关节炎临床疗效观察;朱春来等;《中国社区医师 医学专业》;20121231;第14卷(第12期);第135页正文第1段 * |
| 类风湿关节炎四大主症用药体会;王宗怡;《山东中医杂志》;20040731;第23卷(第7期);第413-414页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103908542A (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102357146B (en) | Traditional Chinese medicine for treating beriberi | |
| CN105535715A (en) | Traditional Chinese medicine skin-wash liquid for treating hot and damp eczema | |
| CN101032593A (en) | Acne-treating Chinese medicine preparation | |
| CN103638190B (en) | The Chinese medicine for the treatment of acute cholecystitis | |
| CN101095899A (en) | Chinese herb medicine for treating coronary heart disease | |
| CN102764360B (en) | Traditional Chinese medicine composition for treating acute cystitis | |
| CN101028490A (en) | Chinese medicine for treating acne | |
| CN104547644A (en) | Bedsore paste | |
| CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
| CN110478416B (en) | Composition for treating rheumatic and rheumatoid arthritis and preparation method and application thereof | |
| CN103908542B (en) | A kind of compound preparation treating rheumatoid arthritis and preparation method thereof | |
| CN103394002A (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN105327285A (en) | Medicine used for treating antral gastritis | |
| CN104173804A (en) | Traditional Chinese medicine for treating nephritis | |
| CN101028491A (en) | Chinese-medicinal preparation for treating ribbon bleb | |
| CN102940806B (en) | Chinese medicinal composition for treating hyperlipidemia | |
| CN1548065A (en) | Compound Chinese medicine for treating chronic pulvic infection and prepn process of its prepn forms | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN110893206B (en) | Externally applied medicine for treating rheumatic arthritis and preparation method thereof | |
| CN101028352A (en) | Chinese-medicinal preparation for treating ischiodynia | |
| CN101028421A (en) | Chinese medicine for treating chronic kidney failure | |
| CN1562201A (en) | Chinese materia medica preparation for treating fracture and preparation method | |
| CN104998189A (en) | Traditional Chinese medicine powder for treating infantile oral ulcer of wind-heat spleen type and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI BAOJI Free format text: FORMER OWNER: ZHAI FENG Effective date: 20150416 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Baoji Inventor before: Di Feng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 043400 LINFEN, SHAANXI PROVINCE TO: 030024 TAIYUAN, SHAANXI PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHAI FENG TO: LI BAOJI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150416 Address after: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant after: Li Baoji Address before: 043400 Shanxi city of Linfen province Quwo County Street Applicant before: Di Feng |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zuo Zhenbai Inventor before: Li Baoji |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160920 Address after: 266000 Shandong city of Qingdao province Jiangsu City Road No. 16 Applicant after: Zuo Zhenbai Address before: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant before: Li Baoji |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161123 Termination date: 20190430 |